OncoHost, a technology company focused on transforming the approach to precision oncology through proteomics and AI, announced on Thursday that it has been honoured as a Gold Winner in the 2025 Merit Awards for Healthcare, with recognition as Technology Solution of the Year.
The Merit Awards for Healthcare are designed to recognise companies delivering breakthrough technologies that meaningfully advance patient care.
OncoHost received top honours for its PROphet platform, an AI-powered, plasma-proteomics solution that predicts patient response to cancer therapy using a single pre-treatment blood sample.
Ofer Sharon, MD, OncoHost CEO, said: "This recognition from the Merit Awards highlights the meaningful clinical value the PROphet platform brings to cancer care. Our goal is to provide oncologists with clear, actionable insights that support more confident and informed treatment decisions from day one. We appreciate this acknowledgment of our team's ongoing work to advance precision oncology."
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
D3 Bio completes USD108m Series B financing round
Champions Oncology expands bioanalytical services with new technology and leadership
Poolbeg Pharma trial to feature in major CRS research programme
Natera acquires Foresight Diagnostics to expand MRD capabilities
OncoHost named Gold Winner in 2025 Merit Awards for Healthcare
Innovent Biologics and Takeda sign global strategic partnership
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
OncoPrecision's ONC001 data selected for presentation at 67th ASH Annual Meeting and Exposition
Immedica gets UAE approval for Zepzelca maintenance treatment